Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03308942
Title Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Tesaro, Inc.
Indications

lung non-small cell carcinoma

Therapies

Niraparib

Niraparib + Pembrolizumab

Dostarlimab-gxly + Niraparib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST